SPRC
SciSparc Ltd.
NASDAQ · Healthcare · Biotechnology · IL
$4.51
+1.35%Year over year
Reported trailing growth
- Revenue
- -34.5%
- EBITDA
- -22.1%
- EBIT
- -19.6%
- EPS
- —
- Free cash flow
- +18.9%
- Operating cash flow
- +18.9%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -14.0%
- EBITDA
- -76.6%
- EBIT
- -19.6%
- Net income
- -93.8%
- EPS
- —
- Free cash flow
- +18.9%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Dec 1, 2025